BH3 mimetic drugs may be useful to treat acute lymphoblastic leukemia (ALL) but the sensitivity of primary tumor cells has not been evaluated. Here B-lineage ALL cell cultures derived from a set of primary tumors were studied with respect to sensitivity to the BH3 mimetics ABT-263 and ABT-199 and to Bcl-2 dependence and function. These ALL cells each expressed high levels of Bcl-2 and exhibited great sensitivity to ABT-263 and ABT-199, which induced rapid apoptotic cell death. BH3 profiling indicated that the ALL cultures were Bcl-2 dependent. Co-immunoprecipitation studies revealed a multi- 
Introduction
Bcl-2 family proteins function as key regulators of intrinsic apoptosis (reviewed in (1) (2) (3) (4) (5) ). They are divided into three main classes: multi-domain anti-apoptotic (or pro-survival) proteins which include Bcl-2, Bcl-xL, Mcl-1 and others; multi-domain pro-apoptotic proteins including Bax and Bak; and BH3-only pro-apoptotic proteins. The BH3-only proteins are divided further into activators (Bid and Bim), which can directly bind and activate Bax and Bak, and sensitizers (Bad, Bik, Hrk, Bmf, Noxa and Puma) which bind anti-apoptotic Bcl-2 proteins and prevent them from sequestering pro-apoptotic Bcl-2 proteins.
Upon activation, Bax and Bak form pores in the mitochondrial membrane for the release of apoptogenic factors such as cytochrome c.
In order to survive in the face of abnormalities such as oncogene activation or genomic instability that would normally trigger cell death, cancer cells must acquire multiple anti-apoptotic mechanisms (6) . Many of the selective blocks in apoptotic signaling in cancer cells involve Bcl-2 family proteins, including overexpression of anti-apoptotic members and/or defects in the activation or expression of pro-apoptotic members (7) . Indeed, Bcl-2 itself was first recognized as a dysregulated and overexpressed gene that plays a key role in promoting survival of follicular lymphoma cells (8) .
Importantly, dysregulation of death signaling not only promotes tumorigenesis but also confers resistance to anti-cancer drugs (9) . It is well established that overexpression of pro-survival Bcl-2 proteins such as Bcl-2, Bcl-xL, or Mcl-1 blocks cell death induced by anti-cancer drugs resulting in chemoresistance (5, 7) . Based on such observations, BH3 mimetics have been developed to target and disable pro-survival Bcl-2 proteins, as a means to overcome the mechanisms of apoptosis resistance and tilt the balance in favor of cell death. ABT-737, and the orally bioavailable derivative ABT-263, are mimetics based on the pro-apoptotic BH3-only protein Bad, which selectively target Bcl-2, Bcl-xL and Bcl-w, but do not inhibit Mcl-1 (10) (11) (12) (13) (14) (15) (16) . ABT-263 has demonstrated in vitro activity in a wide range of cancer cell lines, primary leukemia cells, and xenograft models (10) (11) (12) (13) (14) (15) (16) (17) . Additionally, Phase I and II Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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Because a limitation of ABT-263 is thrombocytopenia due to Bcl-xL inhibition in circulating platelets, the derivative ABT-199 was recently developed, which is selective for Bcl-2 and exhibits anti-tumor activity without significant thrombocytopenia (21) .
Acute lymphoblastic leukemia (ALL) affects both adults and children (22, 23) . Because cure rates have begun to plateau, new classes of therapeutic agents are needed, but these are difficult to evaluate systematically in patients especially in the context of polychemotherapy. Many continuously proliferating ALL cell lines have been established (24, 25) , but after extensive propagation they have likely acquired properties which deviate from the originating primary cells. This emphasizes the need for preclinical cell models of ALL that more closely represent the disease. Recently, conditions were established for the expansion and long-term culture of primary adult ALL cells using a defined media that lacked serum and hematopoietic growth factors (26) . This system provides a unique and powerful tool for the preclinical evaluation of novel therapies for ALL. In the present study, we examined ABT-263 and ABT-199 sensitivity, and Bcl-2 dependence and function, in several of these ALL cultures as well as in freshly isolated pediatric ALL blasts. These results demonstrate the utility of these expanded primary cultures for preclinical studies of ALL, provide mechanistic insight into the determinants of sensitivity and resistance to BH3 mimetics, and have important implications for the optimal use of these compounds in adult and pediatric ALL. 
Cell culture
KB3 cells (HeLa subline) were maintained in DMEM, and RS4;11 and NALM-6 cell lines were maintained in RPMI-1640 medium, supplemented with 10% bovine growth serum, 2 mM L-glutamine, 50 units/mL penicillin, and 50 µg/mL streptomycin. ALL cell cultures were maintained in suspension as described (26) in Iscove's modified Dulbecco's medium (IMDM) containing serum-free supplement (10 µg/mL cholesterol, 6 mg/mL human serum albumin, 0.5 µg/mL amphotericin, 1 µg/mL insulin, 200 µg/mL human apo-transferrin, 50 µM 2-mercaptoethanol, 2 mM glutamine and 50 units/mL penicillin). Mcl-1-dependent and Bcl-2-dependent leukemia cell lines were described previously (27) . Cells were maintained at 37°C and 5% CO 2 . Authentication of the cell lines and ALL cultures was established via short tandem repeat (STR) profiling in September, 2014, by Genetica DNA Laboratories (LabCorp Speciality Testing Group, Burlington, NC). The STR profile of each cell line matched that of reference profiles available in the ATCC database. The primary ALL cell culture profiles did not match any repository cell lines, as expected, and each profile was unique with respect to the others.
Cell viability assay
Cell viability was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as described (28) . Cells (30,000 per well) were seeded in 96-well plates, and either ABT-263 or was added in a fixed final concentration of 0.1% DMSO. After 72h, MTT reagent (50 µg/10 µL/well) was added and incubated overnight at 37°C. The following day, 0.1 mL of 10% SDS in 0.01 M HCl was added, and after overnight incubation, absorbance readings were taken at 540 nm.
BH3 profiling
Whole cell (JC-1) BH3 profiling was performed as described previously (29, 30) . Briefly, cells were harvested, washed, and resuspended in Newmeyer buffer (0.3 M trehalose, 10 mM HEPES-KOH pH 7. 
Retroviral transduction
Retroviral transduction to stably overexpress Mcl-1 in primary ALL cells was performed as described previously (31) . Briefly, full-length human Mcl-1 in pcDNA3.1 vector was cloned into the bicistronic LZRS vector containing a multiple cloning site followed by an Internal Ribosome Entry Site coupled to a truncated form of the nerve growth factor receptor (ΔNGFR) as a marker gene. The constructs were transfected into the ϕ-NX-A retroviral packaging cell line using Fugene HD reagent, and positive cells selected in medium containing 2 µg/mL puromycin. After 24 h in puromycin-free medium, the supernatant was collected, centrifuged to remove cell debris, aliquoted, and quick frozen. For transduction, 0.5 mL of supernatant was added to the wells of a 24-well plate coated with human 7 fibronectin fragments (CH-296, Retronectin, TaKaRa Biotec, Otsu, Japan). Plates were centrifuged at 3,000 x g for 20 min, supernatant was removed, and 1.5 x 10 5 ALL cells were added per well. After 24 h, cells were removed and expanded for four weeks in medium containing serum-free supplement. 
Results

Primary ALL cells express high levels of Bcl-2
We initially selected seven primary adult ALL cell cultures from a total of twelve available samples for which long-term proliferation had been established (26) . These were derived from patients 19, 2, 5, 14, 3, 12, and 6 (26). KB3, a HeLa subline, and RS4;11, a human B-cell ALL cell line, were used as comparative controls. The relative expression level of the three major pro-survival Bcl-2 proteins, Bcl-2, Bcl-xL and Mcl-1, was first examined by immunoblotting (Fig. 1 ). RS4;11 cells and all of the primary ALL cell cultures expressed high levels of Bcl-2 relative to KB3 cells, with quantitation of band intensity indicating levels 150-to 200-fold greater, with the exception of ALL-2 which was about 30-fold greater.
In contrast and despite some variation, the ALL cells expressed levels of Bcl-xL more similar to, and levels of Mcl-1 lower than, KB3 cells.
Primary ALL cells are acutely sensitive to the Bcl-2 inhibitors ABT-263 and ABT-199
Cell viability assays were conducted after 3 day exposure of cells to the Bcl-2/Bcl-xL inhibitor ABT-263 (10) (Supplementary Fig. S1 ). KB3 cells were refractory to the effects of ABT-263, consistent with their strict dependence on Mcl-1 for survival (28) (Fig. S1 and Table 1 ). RS4;11 cells exhibited an IC 50 value of 223 nM while an additional B-ALL cell line, NALM-6, were relatively more resistant with an IC 50 value of 839 nM ( Fig. S1 and Table 1 ). Strikingly, the primary ALL cell cultures were uniformly highly sensitive to ABT-263, with IC 50 values ranging from 2 to 6 nM ( Fig. S1 and Table 1 ). We next tested ABT-199, which is more selective for inhibition of Bcl-2 than Bcl-xL (21) . KB3 cells were unaffected, RS4;11 cells were sensitive, and NALM-6 were relatively resistant (Supplementary Fig. S2 and Table 1 ). As with ABT-263, the primary ALL cell cultures were highly sensitive to ABT-199, with IC 50 values ranging from 3-22 nM ( Fig. S2 and Table 1 ). 
Bcl-2 inhibition leads to rapid apoptotic death of ALL cells
Primary ALL cells are dependent on Bcl-2
To determine whether the primary ALL were dependent on Bcl-2, BH3 profiling was employed (29, 30) . corresponds to the known binding profile of Mcl-1, which has poor affinity for Bad and Hrk, and to previously published BH3 profiling data for this cell line (27, 29, 30) . With the Bcl-2 dependent cell line, loss of mitochondrial membrane potential occurred with peptides from the BH3 domains of Bim, Bid, Puma, Bmf, and Bad, whereas those from Noxa and Hrk were ineffective (Fig. 2) . This corresponds to the known binding profile of Bcl-2, which has poor affinity for Noxa and Hrk, and to previously published BH3 profiling data for this cell line (27, 29, 30) . RS4;11 cells and all of the ALL cell cultures clearly showed the Bcl-2 dependent profile (Fig. 2) , indicating their Bcl-2 dependence and consistent with their high level of sensitivity to ABT-199.
Bcl-2 sequesters several pro-apoptotic Bcl-2 family members
We next sought to identify by co-immunoprecipitation which pro-apoptotic Bcl-2 family proteins were bound to Bcl-2. RS4;11 cells and the primary ALL cultures expressed, with varying relative levels, several pro-apoptotic Bcl-2 family members, including Bak, Bax, Bid, Bim and Bik (see lane 1 in Figs. 3A and 4A).
Bcl-2 was first immunoprecipitated from RS4;11 cells (Fig. 3A) and efficient immunoprecipitation was demonstrated as Bcl-2 appeared mainly in the pellet (lane 5) and was depleted from the supernatant (lane 3), whereas in a mock immunoprecipitation performed in the absence of antibody, the protein remained in the supernatant (lane 2) and was absent from the pellet (lane 4). Immunoblotting for proapoptotic Bcl-2 proteins in the precipitated material showed bands which appeared to correspond to Bak, Bax, several forms of Bim (Bim-EL, Bim-L, and Bim-S), and Bik, although Bid, despite being present in the extract, was not detected (Fig. 3A) . Identification of Bak, however, was complicated by the presence of two bands, one at 23 kDa and an additional band, presumably immunoglobulin light chain (IgG-LC) at around 25 kDa, migrating with a slower mobility (Fig. 3A, lane 5) . We reasoned that the binding of Bak to Bcl-2 in the immunoprecipitate might be disrupted under mild detergent conditions such as 1% Triton X-100, whereas IgG-LC and Bcl-2 may remain more firmly bound to the Protein A/G beads under such conditions. To test this, Bcl-2 was immunoprecipitated from RS4;11 cells, and the 
washed beads incubated in buffer containing 1% Triton X-100, and the detergent-solubilized eluant subjected to immunoblotting (Fig. 3A, lane 7) . Immunoblotting for Bak detected only the band at 23 kDa, indicating that the detergent elution step is useful in positive identification of proteins specifically bound to Bcl-2. Consistent with the ability of Triton X-100 to remove more loosely bound proteins from the beads, Bcl-2 itself was absent from the eluted material (Fig. 3A, lane 7) . Bax was not detected in the detergent eluant, confirming that the band present in the immunoprecipitate (lane 5, asterisk), which ran slower than authentic Bax, was likely due to IgG-LC cross-reactivity. Strong bands corresponding to the three forms of Bim as well as Bik were clearly identified in the detergent eluant, confirming them as authentic Bcl-2 partners. Reciprocal immunoprecipitations were performed for further validation, and Bcl-2 was identified in immunoprecipitates of Bim (Fig. 3B ) as well as Bik (Fig. 3C ) but was not detected in an immunoprecipitate of Bax (data not shown). Thus in RS4;11 cells, Bcl-2 binds several pro-apoptotic partners including Bak, Bim and Bik, but does not appear to bind either Bax or Bid. To further verify the specificity of these interactions, immunoprecipitation with β-actin antibody as a negative control was performed. As shown in Supplementary Fig. S4 , when β-actin was immunoprecipitated from an extract of RS4;11 cells, β-actin was detected whereas Bak, Bax, Bid and Bim were not detected. Interestingly, Bcl-2 was present in the β-actin immunoprecipitate, consistent with several reports suggesting these proteins interact (32, 33) . Thus Bcl-2 exists in at least two complexes, with pro-apoptotic Bcl-2 proteins and with β-actin.
One of the ALL primary cultures, ALL-19, was chosen for similar examination of Bcl-2 complexes, and with one exception, similar results were found. Thus Bak, Bim and Bik, but not Bid, were each positively identified in Bcl-2 immunocomplexes (Fig. 4A) . A band appearing to correspond to Bax was also present in the Bcl-2 immunoprecipitate (Fig. 4A, lane 5) , and its identification was strengthened as the same band was detected in the detergent eluant (Fig. 4A, lane 7) . Reciprocal immunoprecipitations 
ABT-263 displaces Bim from Bcl-2
The sensitivity of ALL cells to ABT-263 is likely based on the ability of the mimetic to bind directly to Bcl-2 and displace bound pro-apoptotic Bcl-2 proteins. We initially focused on Bim because it is a key activator BH3-only protein and found associated with Bcl-2 in ALL cells. To test the effect of ABT-263 on Bim:Bcl-2 interaction, RS4;11 cells were treated with vehicle or 1 µM ABT-263 for 4 or 6 h, and whole cell extracts were prepared, Bcl-2 immunoprecipitated, and subjected to immunoblot analysis for both Bcl-2 and Bim. As shown in Supplementary Fig. 5 , lanes 9-11, while the levels of Bcl-2 in the immunoprecipitate remained unchanged, the levels of Bim, and most notably Bim-EL, were reduced following ABT-263 treatment. These results show that ABT-263 reduces the amount of Bim associated with Bcl-2 in RS4;11 cells, consistent with the mimetic acting to directly displace Bim from Bim:Bcl-2 complexes.
Mcl-1 overexpression renders ALL cells ABT-263/199 resistant
To further establish that the primary ALL cells are sensitive to the BH3 mimetics because of their strict (Fig. 5A) . Cell viability assays showed that even at the highest concentrations tested of 1 µM, ABT-263 reduced viability by only 40% (Fig. 5B ) and ABT-199 was essentially ineffective (Fig. 5C) . 
Freshly isolated pediatric ALL blasts are highly sensitive to ABT-263
To further establish that primary ALL cells are highly sentive to Bcl-2 inhibtion, and to extend the study to include samples derived from pediatric patients, blasts were freshly isolated from two pediatric patients diagnosed with ALL. Immunoblotting indicated that the pediatric ALL cell cultures displayed anti-apoptotic Bcl-2 protein expression profiles similar to that observed for the adult ALL cultures, with high levels of Bcl-2, similar levels of Bcl-xL, and lower levels of Mcl-1, versus KB3 cells (Fig. 6A) . Cell viability assays showed that both samples of the pediatric ALL blasts were highly sensitive to ABT-263, with IC 50 values of 6.2 ± 0.3 nM and 6.7 ± 0.4 nM (Fig. 6B, 6C) . (35) , and in another study four ALL cell lines varied over a 100-fold range in ABT-263 sensitivity (17) . In addition and aside from ALL, a study of twenty five multiple myeloma cell lines reported IC 50 values for ABT-263 ranged from 7 nM to 150 nM (36) . In the current work, the B-cell ALL cell lines RS4;11 and NALM-6 were much more resistant to ABT-263 versus the most sensitive ALL culture (Table 1) . Interestingly, RS4;11 cells were much more sensitive to ABT-199 than NALM-6 cells ( Table 1 ), suggesting that NALM-6 may be more dependent on Bcl-xL than Bcl-2. Importantly, freshly isolated pediatric ALL blasts exhibited IC 50 values for ABT-263 similar to those of the adult ALL primary cultures. The uniformity of response observed with the ALL cultures versus the large variation seen with established cell lines has two important implications. Firstly, it supports the prevailing notion that, over time, cell lines acquire characteristics that may not reflect those of the primary cells from which they were derived. Secondly, this disparity indicates that primary ALL cultures are much more sensitive to BH3 mimetics, and more uniform in their response, than suggested by data generated from the study of cell lines. In turn these findings highlight (29) . Applying this technique (Fig. 2) , we found that RS4;11 cells and the primary ALL cell cultures exhibited a BH3 profiling signature characteristic of cells dependent on Bcl-2. Interestingly though, the primary cultures were much more sensitive to ABT-263, up to 100-fold, than RS4;11 cells. Furthermore, ALL-2, which had the lowest relative expression of Bcl-2 ( Fig. 1) , was among the most sensitive to ABT-263 (Table 1) (Fig. 5) .
However, endogenous levels of Mcl-1 were similar for RS4;11 cells and the primary ALL cultures, so this parameter alone cannot explain the differential response. A recent study has shed light on determinants of ABT-263 sensitivity (40) . It was found that cells sensitive to ABT-263 expressed high levels of both Bcl-2 and Bim, and furthermore that a critical function of Bim was to be available to bind and inhibit Mcl-1. These findings are consistent with others which have shown a key role for Bim:Bcl-2 complexes in ABT-263 responsiveness (37, 41, 42) , and furthermore suggest that in addition to its Overall, the data available to date highlight the complex underpinnings of the ABT-263 response.
It is well established that a key role for anti-apoptotic Bcl-2 proteins is sequestration and inactivation of pro-apoptotic Bcl-2 family members. While Bcl-2 potentially can bind many proapoptotic family members, the number and nature of binding partners in specific contexts have not been fully explored. Co-immunoprecipitation was used to identify the spectrum of pro-apoptotic Bcl-2 proteins bound to Bcl-2, and the results demonstrated the multifaceted role of Bcl-2 in binding several pro-apoptotic Bcl-2 proteins (Fig. 3 and 4 compounds targeting anti-apoptotic Bcl-2 proteins (12) (13) (14) , there are now many more agents and combinations than can be systematically studied clinically. In addition, the drug responsiveness of established cell lines may differ from the primary cells from which they were derived. Thus there is an urgent need for appropriate cancer cell culture models, and advances in preclinical drug development will increasingly depend on these. The results presented here indicate that the ALL cell cultures represent a valuable model system for preclinical testing of novel agents and drug combinations for ALL. Bim was immunoprecipitated from RS4;11 cells, and subjected to immunoblotting for Bim and Bcl-2. C.
Bik was immunoprecipitated from RS4;11 cells, and subjected to immunoblotting for Bik and Bcl-2. 
